Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Hookipa Pharma ( (HOOK) ) is now available.
On July 29, 2025, HOOKIPA Pharma Inc. held a special meeting of stockholders where they voted on several significant proposals. The stockholders approved the sale of certain assets to Gilead Sciences, Inc., the liquidation and dissolution of the company, and the potential adjournment of the meeting to solicit additional proxies if needed.
The most recent analyst rating on (HOOK) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Hookipa Pharma stock, see the HOOK Stock Forecast page.
Spark’s Take on HOOK Stock
According to Spark, TipRanks’ AI Analyst, HOOK is a Underperform.
Hookipa Pharma’s stock is rated very poorly due to several critical issues. The company’s financial performance is weak, with no revenue and persistent losses indicating severe financial instability. The technical analysis suggests a bearish trend with the stock being oversold, but lacking any positive momentum. Valuation metrics are alarming, with a negative P/E ratio and no dividend yield. The corporate decision to delist and dissolve further exacerbates the negative outlook, indicating a lack of future viability and potential loss for investors.
To see Spark’s full report on HOOK stock, click here.
More about Hookipa Pharma
Average Trading Volume: 157,131
Technical Sentiment Signal: Sell
Current Market Cap: $11.2M
For a thorough assessment of HOOK stock, go to TipRanks’ Stock Analysis page.